The fight against the COVID-19 pandemic is not over, and we still need safe and effective drugs that can treat hospitalized patients. Dexamethasone and other drugs used in standard therapies are not enough for some drugs, so the World Health Organization is starting new clinical trials with three other drugs. This is their nature and how they work.
World Health Organization (WHO) Will start experiment Three drugs Approved for others disease fighting Coronavirus disease,by Coronavirus SARS-CoV-2.this isInfliximab monoclonal antibody, DellArtesunate antimalarial drug withAnti-tumor imatinib, Each has its own characteristics, but all have characteristics Anti-inflammatory (medicine.These drugs should help Rabies Be hospitalized, resist or prevent catastrophic events immune response It can follow a virus and is usually fatal.Scientists hope that in concern Due to preventive measures, preventive measures for COVID-19 have been completed vaccine.
This Vaccination campaign In fact, in many countries, treatments for the SARS-CoV-2 coronavirus are developing rapidly, with the goal ofHerd immunity In the next few months, before the cold season reappears, it is known to cause respiratory pathogens.It turns out that the vaccine has been approved for emergency use Effective and safe, Can break down the infection, but most importantly, Hospital admission ei death toll, Data from Israel and the United Kingdom show that the direction of vaccination is far ahead. However, for activists who need medical assistance, problems still exist.Even though Italy They still count Hundreds died The only way to stop this massacre every day is to make this disease as effective as a preventive vaccine, and this massacre has killed 3.3 million people.
Drugs that invested heavily in the first phase of the pandemic, such as Redesivir, A combination of antiretroviral drugs Lopinavir and Ritonavir, L’Hydroxychloroquine, L’Interferon And the others did not actually show a decrease mortality rateLike Corticosteroid immunosuppressant dexamethasone. Its effectiveness in hospitalized patients is related to the fact that it manages to counteract the so-called “cytokine storm”, which is an excessive immune response to the SARS-CoV-2 coronavirus invasion and is more dangerous than the infection itself. This is one of them, and it is no coincidence. complication The potentially fatal COVID-19 can trigger Acute respiratory distress syndrome (ARDS).he Dexamethasone It has been shown to reduce mortality by 30%, but not everyone can respond to treatment.Three new drugs that WHO will test in this project help each other The exact purpose is to expand and improve the arsenal available to doctors to save the lives of Covid patients who do not respond to other therapies.
Monoclonal antibodies Infliximab, Want to fight Autoimmune disease Such as Crohn’s disease and rheumatoid arthritis, such as Article in Nature It can block a protein called “Tumor Necrosis Factor Alpha” (TNF-α); it is released Macrophages And catalyzeinflammation.Antitumor Imatinib, In addition to reducing the activity of proteins that cause inflammation (Cytokines), yes Prevent viruses from entering cellsThis is the key process of virus replication and infection.Not like batteryIn fact, viruses need host cells to replicate, so they are much more difficult to fight against drugs than the former (the latter fights antibiotics).The third drug will involve experiment IsArtesunate, An anti-malarial drug, has “potential anti-inflammatory effects.”
“Each of these drugs will be provided at the same time as standard care, including dexamethasone in many areas” He has announced The scientific director of the Norwegian Institute of Public Health and the head of the Umoja International Steering Committee, Professor John-Arne Røttingen is called this because it aims to determine a safe, effective and safe environment. low cost Can be easily distributed all over the world. Details about the new trial have been published in the article “International COVID-19 trial restarted with focus on immune response“Su Nature.